Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Revenue of Celltrion, Inc. (068270.KS)
Revenue in 2023 (TTM): $1.56 B
According to Celltrion, Inc.'s latest financial reports the company's current revenue (TTM) is $1.56 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Celltrion, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $1.56 B | $725.51 M | $643.95 M | $481.64 M | $384.43 M |
| 2022 | $1.64 B | $741.15 M | $575.52 M | $449.4 M | $386 M |
| 2021 | $1.37 B | $793.61 M | $687.78 M | $539.21 M | $415.87 M |
| 2020 | $1.33 B | $737.54 M | $599.9 M | $471.63 M | $371.59 M |
| 2019 | $809.88 M | $454.65 M | $384.15 M | $274.18 M | $216.05 M |
| 2018 | $704.82 M | $395.38 M | $321.2 M | $216.48 M | $176.38 M |
| 2017 | $681.14 M | $500.83 M | $428.8 M | $346.69 M | $264.27 M |
| 2016 | $481.27 M | $284.64 M | $237.93 M | $164.59 M | $127.74 M |
| 2015 | $433.06 M | $264.71 M | $197.21 M | $117.06 M | $110.59 M |
| 2014 | $338.06 M | $244.83 M | $189.47 M | $107.02 M | $80.87 M |
| 2013 | $162.35 M | $113.05 M | $105.56 M | $83.01 M | $73.53 M |
| 2012 | $251.33 M | $183.93 M | $173.05 M | $134.61 M | $125.19 M |
| 2011 | $200.26 M | $162.76 M | $145.19 M | $131.61 M | $120.43 M |
| 2010 | $129.86 M | $101.57 M | $89.57 M | $78.84 M | $77.78 M |
| 2009 | $104.46 M | $67.43 M | $58.07 M | $47.66 M | $42.02 M |
| 2008 | $60.06 M | $34.13 M | $25.9 M | $12.64 M | $10.46 M |
| 2007 | $43.12 M | $6.62 M | $4.34 M | $191.8 K | $1.64 M |